Two Directors at Transocean Ltd sold 196,911 shares at 5.000USD. The significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI NCI-Led Study Shows Median PFS of 9.6 Months Results Presented at AACR Special Conference on Innovations in Prostate Cancer PRINCETON, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that results of a ...
Chop Continues; Nasdaq 100 Testing Major Resistance We maintain our near-term bullish outlook on the S&P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM), which has remained in place since 4/22/25, aside from one week (11/19/25-11/25/25) when we went to neutral. We will stay near-term bullish as long as crucial support levels of 6824 on SPX, $610 on QQQ, and $245 on IWM continue to hold. We see mild deterioration in market dynamics, which may provide a near-term headwind; still, MAG7 earning...
Transocean Ltd. Announces Fourth Quarter 2025 Earnings Release Date STEINHAUSEN, Switzerland, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Transocean Ltd. (NYSE: RIG) announced today that it will report earnings for the fourth quarter 2025 and issue a fleet status report on Thursday, February 19, 2026, after the close of trading on the New York Stock Exchange. The company will conduct a teleconference starting at 9 a.m. EST, 3 p.m. CET, on Friday, February 20, 2026. Individuals who wish to participate in the teleconference should dial approximately 15 minutes prior to the scheduled start time an...
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 Patent Enhances IP Estate for Lead Asset; Combined with Anticipated Biologics Exclusivity, Market Protections Extend Over 20 Years PRINCETON, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the U.S. Patent Office has issued a Notice of Allowance for the Company’s lead asset, PDS0101. Once issued, the new patent (U...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Golub Capital BDC, Inc. (GBDC) and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 7 January 2026 in which we reassessed the appropriateness of the ratings in ...
PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint PDS Biotech Submits Amended Protocol for Phase 3 VERSATILE-003 Trial Constructive Type C Meeting Provides Potential Pathway to Accelerated Approval of PDS0101 PRINCETON, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company has submitted a protocol amendment to the U.S. Food & Drug Admini...
Transocean Ltd. Announces Contract Award and Extension Totaling $168 Million STEINHAUSEN, Switzerland, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Transocean Ltd. (NYSE: RIG) (“Transocean”) today announced a contract award and an extension, respectively, for two of its drilling rigs. Together, the fixtures represent approximately $168 million of firm backlog. In Brazil, the Deepwater Mykonos was awarded a contract with bp. The estimated 302-day campaign is expected to begin in the third quarter of 2026 and contribute approximately $120 million in backlog, excluding additional services and compen...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.